Over the past 2 decades, there has been an extraordinary progress in the regimens
developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive
breast cancer. Trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine (T-
DM1) are commonly recommended anti-HER2 target agents by the US Food and Drug
Administration. This review summarizes the most significant and updated research on
clinical scenarios related to HER2-positive breast cancer management in order to revise the …

Simple Summary The development of several antiHuman Epidermal Growth Factor
Receptor 2 (HER2) treatments over the last few years has improved the landscape of HER2-
positive breast cancer. Despite this, relapse is still the main issue in HER2-positive breast
cancer. The reasons for therapeutic failure lie in the heterogeneity of the disease itself, as
well as in the drug resistance mechanisms. In this review, we intended to understand the
milestones that have had an impact on this disease up to their implementation in clinical …